Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
09:20am, Thursday, 14'th Aug 2025
Kelowna, British Columbia – TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platform
Global Partners (GLP) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Tuesday, 12'th Aug 2025
Global Partners (GLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Tuesday, 12'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Best Value Stocks to Buy for August 12th
06:40am, Tuesday, 12'th Aug 2025
ESEA, GLP and HRTG made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 12, 2025.
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 11'th Aug 2025
Global Partners (GLP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
10:00am, Saturday, 09'th Aug 2025
This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals. The news jolted the health care sector, which fell by 2.74% over the past f
Global Partners LP Common Units (GLP) Q2 2025 Earnings Call Transcript
01:15pm, Thursday, 07'th Aug 2025
Global Partners LP Common Units (NYSE:GLP ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Eric S. Slifka - President, CEO & Vice Chairman of Global GP LLC Gregory B.
Global Partners (GLP) Q2 EPS Falls 50%
11:09am, Thursday, 07'th Aug 2025
Global Partners (GLP) Q2 EPS Falls 50%
Hims & Hers: A High-Risk Bet
10:27am, Thursday, 07'th Aug 2025
Upgrading Hims & Hers Health, Inc. to a speculative Buy after a 20% post-earnings selloff, given management's reaffirmed guidance and near-term demand for personalized compounded GLP-1s. I believe the
Global Partners Reports Second-Quarter 2025 Financial Results
08:00am, Thursday, 07'th Aug 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the second quarter ended June 30, 2025. CEO Commentary “F
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved th
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
01:21pm, Wednesday, 06'th Aug 2025
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
01:00pm, Wednesday, 06'th Aug 2025
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nor
There Is Only 1 GLP-1 Stock to Buy In 2025
11:35am, Wednesday, 06'th Aug 2025
Key Points in This Article: Ozempic's introduction shifted obesity treatment from lifestyle to pharmacological solutions, using GLP-1 drugs to regulate appetite and glucose.
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
09:20am, Wednesday, 06'th Aug 2025
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria
